The evolution of bispecific antibodies in multiple myeloma - PubMed
3 days ago
- #immunotherapy
- #bispecific antibodies
- #multiple myeloma
- The treatment of multiple myeloma (MM) has advanced with CD38-targeting monoclonal antibodies like daratumumab and isatuximab.
- B-cell maturation antigen (BCMA)-targeting therapies, including CAR-T cell therapy and antibody-drug conjugates, have improved outcomes for relapsed/refractory (R/R) MM.
- Bispecific antibodies (BsAbs) targeting CD20 and CD3 are used in R/R B-cell lymphoma and are being developed for MM with targets like BCMA, GPRC5D, and FcRH5.
- Four BsAbs—teclistamab, elranatamab, linvoseltamab, and talquetamab—are FDA-approved for R/R MM.
- The paper reviews the mechanism of action, clinical activity, and resistance mechanisms of BsAbs in MM.
- Novel strategies include combining two BsAbs (e.g., teclistamab and talquetamab) or developing trispecific antibodies to enhance efficacy and overcome resistance.